Earnings ·
AstraZeneca reports Q3 Core EPS of $2.79 and reconfirms FY guidance
AZNAstrazeneca PLC
AstraZeneca reported third-quarter total revenue of $16.2 billion, a 7% increase at constant exchange rates, driven by double-digit growth in Oncology, Respiratory & Immunology, and Rare Disease. Core earnings per share rose 17% to $2.79, while core operating profit increased 20%. The company reconfirmed its full-year guidance for mid-to-high single-digit total revenue growth and low double-digit core EPS growth at constant exchange rates. Additionally, AstraZeneca announced a $2 billion equity investment in Summit Therapeutics and initiated a restructuring program expected to cost up to $2 billion over three years while delivering $1.5 billion in annualized pre-tax benefits.